New RA drug TLL-018 goes Head-to-Head with tofacitinib in phase 3 trial
Disease control
Ongoing
This study tests a new drug called TLL-018 against an approved drug, tofacitinib, in people with active rheumatoid arthritis who did not get enough relief from or could not tolerate biologic treatments. About 459 adults aged 18–65 will take either TLL-018 or tofacitinib for sever…
Phase: PHASE3 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 26, 2026 09:28 UTC